Comparing Enanta Pharmaceuticals (ENTA) and The Competition

Enanta Pharmaceuticals (NASDAQ:ENTA) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Enanta Pharmaceuticals to similar companies based on the strength of its dividends, valuation, earnings, risk, analyst recommendations, institutional ownership and profitability.

Insider & Institutional Ownership

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Enanta Pharmaceuticals has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals’ competitors have a beta of -3.81, suggesting that their average share price is 481% less volatile than the S&P 500.

Earnings and Valuation

This table compares Enanta Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32 million	-$81.89 million	-4.81
Enanta Pharmaceuticals Competitors	$3.56 billion	$3.19 billion	552.49

Enanta Pharmaceuticals’ competitors have higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Enanta Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Enanta Pharmaceuticals Competitors	-2,380.61%	-219.90%	-15.56%

Analyst Ratings

This is a breakdown of current recommendations for Enanta Pharmaceuticals and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1	0	3	0	2.50
Enanta Pharmaceuticals Competitors	7776	13772	25741	1037	2.41

Enanta Pharmaceuticals presently has a consensus price target of $19.00, suggesting a potential upside of 63.79%. As a group, “Pharmaceuticals” companies have a potential upside of 24.80%. Given Enanta Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Enanta Pharmaceuticals is more favorable than its competitors.

Summary

Enanta Pharmaceuticals beats its competitors on 7 of the 13 factors compared.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.